Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
very ugly L2 - 500K shares for sale at .025 and almost 2 million at .03
I meant I don't think they will PR when the meeting will be. I think we will hear something from the company after they have the meeting with the FDA.
Not sure if they will PR the meeting date, but more importantly the results of it. I wouldn't expect an update in the next couple months unless something drastically changes.
I got my bid in for .0165 :)
looks like this is going to break .02!!!!
WOW this getting very ugly!!!!
Seems like we are getting setup for some major news to hit. I see the price is holding strong in the .003's
CEO presenting at the Sidoti & Company Spring 2017 Convention in NYC at the end of the month. More eyes are going to be on bicx and investors will see the value. I am temped to add more as we may get a spike after the conference. I also wouldn't be surprised if we get an update from the company before the presentation.
The million dollar question is is that enough for an FDA fast track?
We have been getting regular updates from the company every few weeks. FDA is a slow government agency so we are at their mercy.
TGTX is a beast
I bought some at .09 - lol
If they get the fast track it's going to $30 IMO
more dumping everyday. I am a buyer again when it breaks .01
I think if the company released some clean positive news it would go a long way for the stock price. I wonder if there is another raise in the low .30's coming??
More dumpage and another t-trade....
Please wake me up when the game starts. It's just been commentary for over 3 year for me. It's time to start playing in my book and nothing less. No more excuses and delays.
I love the way this is trading! Any selling is immediately absorbed. We have some major accumulation going on.
Listen to the I interview with the CEO. He says "the trials have been consistent with their goals."
Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps
TG Therapeutics changed the design of the GENUINE study last October to eliminate progression-free survival (PFS) as a co-primary endpoint, leaving only overall response rate. The planned enrollment was also cut from 330 to 120 patients. The changes allowed TG Therapeutics to complete the GENUINE study faster, but it also nullified the Special Protocol Assessment (SPA) reached with the FDA spelling out the regulatory requirements for ublituximab's approval.
FDA is often displeased when companies renege on SPAs and fail to provide the previously agreed-upon clinical data necessary for approval.
While TG Therapeutics acknowledges the added risk of the lost SPA, the company still intends to meet with the FDA "to discuss the filing of the data for accelerated approval." The company's supporters argue the nearly doubling of the response rate in ublituximab's favor should be strong enough clinical evidence for FDA to approve.
The question of medical need for previously treated, high-risk CLL patients is the other, simmering issue. TG Therapeutics bears make the point these patients can be treated today with a combination of Rituxan, Roche's long-approved anti-CD20 monoclonal antibody, and Imbruvica. Therefore, ublituximab is not filling an unmet medical need and accelerated approval should be off the table.
Bulls counter with the argument that Rituxan is not specifically approved for use in previously treated, high-risk CLL patients. Doctors prescribe Rituxan/Imbruvica off label. From an FDA perspective, therefore, an unmet medical need still exists.
[TG Therapeutics is a member of the Gnarly Nine. Read more here.]
I had lunch Thursday with a healthcare fund manager and longtime TG Therapeutics shareholder. We talked about the ublituximab CLL-approval controversy. His reaction: Bemused. He owns TG Therapeutics for ublituximab but because he believes the drug will eventually be approved for multiple sclerosis (following the development plan used by Roche to win the approval of ocrelizumab -- another anti-CD20 monoclonal antibody.)
My TG Therapeutics shareholder/lunch date didn't participate in this week's $50 million stock offering, but he suspects (but doesn't know for sure) that the funds who did were also more interested in ublituximab-multiple sclerosis than ublituximab-CLL.
https://www.thestreet.com/story/14036467/1/biotech-stock-mailbag-puma-s-rebound-explained-tg-therapeutics-approval-debate-aurinia-next-steps.html
Big O - this has all the info you are looking for:
Great radio interview with CEO Brady Grainer
https://upticknewswire.com/brady-grainer-ceo-for-biocorrx-reaches-agreement-with-city-of-anaheim-to-treat-opioid-addiction/
This is nothing new since the deal was done last June. How is getting a 5mm investment bad with a purchase price of .02 when the stock was trading in the .03-.04 range at the time of the deal? FDA approval is an expensive process and it's great BICX is funded.
VNDM on the offer is not good.
Anyone notice the slow accumulation at .10? Smart buyer is letting the seller come to his/her bids a little bit at a time to keep that price range.
All those shares are restricted for at least a year. Remember, the deal was done when the stock was trading at .03 and Alpine is a legit investment shop that is helping BioCorRx grow the company, so it's NOT a toxic lender who is going to dump their shares and tank the stock. I am sure Alpine is in for the big payday that will come from FDA approved and/or buyout.
earnings are a non-event for biotechs not selling any drugs yet
I owed options last year, but expired worthless. When the company announced they were changing the trial the stock kinds tanked. I bought shares when it hit $10 other day.
This is when the stock was at .03 last year. This is actually not a bad deal, most OTC stocks have to take terrible terms giving away tons of shares at an 80% discount.
This was the rest of raise they started last year. Clinical trials for the FDA are expensive so it's a necessary evil.
I think they are meaningless at this point. It's all about bringing the drug to market.
this monster is going to break $12 today - TGTX
last time I checked dilution usally makes a stock go down.. TGTX is a beast...
Ritz, we were at this point over 3 years ago. it just simply does not cut it anymore. We need a real deal with a real company - plain and simple.
Text book going into FDA approval. TGTX is raising the needed cash and putting their blockbuster leukemia drug to market. IMO, $30 stock before the fall.
Tons of accumulation going in in the .11-.13 range. IMO, any positive FDA up date we move into the .20's.
I saw a $18 target by H.C. Wainwright, but I think that is only the beginning.
Great radio interview with CEO Brady Grainer
https://upticknewswire.com/brady-grainer-ceo-for-biocorrx-reaches-agreement-with-city-of-anaheim-to-treat-opioid-addiction/
reminder for everyone:
7 Sure Signs That You Should Not Be Playing The Stock Market (at least not the Penny Markets anyway) big smile
1. You Believe That The Share Price of Your Penny Stock Is Down Because of Shorting
No, no, no! Impossible! We'll say it again. It is impossible for a significant short position to exist in any penny stock. Anybody who tells you otherwise is conning you. Any tout who tells you that his "pick" went down because of shorting is a liar. There is only one reason for a penny stock to go down in price. And that is because sellers (mostly insiders) are flooding the market with stock.
2. You Believe That There Is Such A Thing As A "Paid Basher"
The fact of the matter is that most penny stocks are scams. The regulators have made it far too easy for con artists to infiltrate the stock market with ridiculous schemes, most of which are designed to dump worthless stock onto an unsuspecting public. In order for these cons to get you to buy their stock, their company has to be "talked up" and that is through paid promoters who have developed email or snail mail lists by advertising their own feigned success in the penny markets. Some of these promoters are so good at conning their audience, they even convince subscribers to pay for their membership. Most, but not all, will specify some sort of compensation for their promotion, as required by law.
When a penny stock goes down, touts and company insiders will often invoke the idea of shorting as the cause. As discussed previously, shorting penny stocks is so prohibitive, that it never causes the demise of the price of a penny stock. Still, people will try and convince you that anybody speaking negatively about the prospects of a penny stock is a "paid basher" out to aid the shorts. As there is no upside to paying somebody to speak negatively about a penny stock, paid bashers are a fairy tale. Same goes for these fantasy so-called "short and distort" schemes. If you believe that the share price of a penny stock can go down because of a paid basher, GET OUT OF THE MARKET NOW!
3. You Think That A Stock Can Have More Buyers Than Sellers or Vice Versa
Every trade requires a buy and a seller. Period. There is no such thing as more buys than sells or more sells than buys. Think of a stock as a car. If you are looking to buy, you know how much you are willing to spend. Same with a stock. You make a bid and if the seller is willing to sell it to you at that price, then you have a deal. But there is still a buyer and a seller. Same if you are selling a car. You know what price you want and if the buyer meets your price, then you have a deal. Once again, you still have a seller and a buyer. It takes two to tango and two to complete a transaction. A stock, like a car, boat or house is only worth what somebody will pay for it.
4. You Think That Penny Stocks Can Be Charted
The concept of relying on charts to determine when a penny stock should be bought and sold is one of the most ridiculous theories out there. Chartology is unreliable at the best of times even with legitimate stocks. Penny stocks are at most times manipulated and Bolinger Bands or Candlestick analysis cannot ever be relied on to indicate buy or sell signals. In fact, applying these theories or others like them, is guaranteed to give you a wrong answer every time. Even those that devised these analytical techniques will tell you that they cannot apply to penny stocks. Once a promotion of a penny stock ends, there is no logic as to where it will trade, except that it will trade lower.
5. You Believe That If The Company Makes A Statement, It Is Guaranteed to Be Truthful
There is still the perception out there that regulators like the SEC check out every statement a company make for legitimacy. Or that the regulators will catch and prosecute a stock schemer every time. Not even close to true. Most securities fraud artists, especially in the penny markets, get away scot-free. Even those that are eventually prosecuted, can spend years spinning their cons before they are stopped.
A press release or SEC filing issued by a company involved in a pump and dump scheme rarely speaks the absolute truth, if at all. At a minimum, the truth is distorted with a positive bent to make the announcement seem better than it is. Many are just outright fabrications. It bears repeating, that you should look for the caveats in announcements, which will eventually lead to an easy out for the announcer. For example, financing of up to x dollars. An option to acquire... Will buy back up to x dollars of stock from time to time at the discretion of the Board of Directors. Our favorite term is "best efforts".
6. You Believe That Paying A Tout For Penny Stock Picks Makes the Pick More Legitimate
It is unfathomable that some touts garner fees from their subscribers. These are promoters getting paid from both sides. Almost always, they are promoting the same stock that the "free" touts are promoting.
7. You Believe That Trading In Penny Stocks Is Indicative of The Major Markets
We laugh when we hear someone claim that their penny stock was down because the DOW was also down on the day. How preposterous. Except perhaps in the event of a horrendous day on the major markets (like a crash), when everyone is jittery, penny stocks are absolutely not indicative of the major markets. Most penny stocks go up because of independent promotions and most go to down when the promotion ends or insider selling weighs on the share price. The performance of the DOW or any other major index generally has no relevance to the performance of penny stocks.
Remember 75% of Alkermus sales are from VIVITROL so that's about 200mm a year in sales and maybe 275 million in total sales of all their products.
ALKS market cap = 9 billion
BICX market cap = 19 million
That means ALKS is trading at over 30x it's annual sales. If BICX only took in 10% of those sales that's 30 million a year. 30x those annual sales and BICX market cap would be an easy 900 million, which is $6 a share!
Alkermus Addiction Injection Drug:Vivitrol
Net sales of VIVITROL for Quarter were $62.1 million
https://finance.yahoo.com/news/alkermes-plc-reports-financial-results-120000774.html
Surwin, what's the TA if we break through .02?